AQST vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AQST exhibits severe financial distress despite modest revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports massive negative profitability metrics, including a -188.09% profit margin and -33.92% ROA, with no meaningful earnings or cash flow generation. Insider selling totaling $1.86M over six months, including significant sales by top executives, signals deep skepticism about future prospects. While the stock trades below its 52-week high and has a strong analyst consensus, the lack of intrinsic value support and deteriorating earnings trends undermine long-term viability. The absence of a valid Altman Z-Score and Graham Number further limits fundamental valuation reliability.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AQST vs JNJ: Head-to-Head Comparison
This page compares Aquestive Therapeutics, Inc. (AQST) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.